Vertex Unveils More Upbeat Hep C Drug Data

Patients were treated with 12 weeks of telaprevir plus interferon and ribavirin, followed by another 12 weeks of interferon and ribavirin alone.

There is a control arm in the PROVE 3 study, but these patients are still being followed. At this point, 8% of these patients retreated with standard therapy (interferon and ribavirin) had undetectable levels of virus after 12 weeks of treatment. After 36 weeks of treatment, the undetectable level rose to 30%.

While the control arm patients appear to be doing better with longer re-treatment, Vertex's Alam says most of these difficult-to-treat patients must reach undetectable levels by week 12 if they have any real chance for a long-term cure. Most of the patients who reach undetectable levels after 12 weeks of treatment ultimately relapse again, he says.

« Previous Page

1 2 3

Next Page »